An evidence-based terlipressin therapy for gastroesophageal variceal hemorrhage
10.3760/cma.j.issn.1007-3418.2018.04.002
- VernacularTitle: 特利加压素治疗食管胃静脉曲张出血的循证医学依据
- Author:
Xinmiao ZHOU
1
;
Xingshun QI
2
;
Jidong JIA
3
Author Information
1. Graduate School, Jinzhou Medical University, Jinzhou 121000, China
2. Department of Gastroenterology, General Hospital of Shenyang Military Area, Shenyang 110840, China
3. Center for Liver Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
- Publication Type:Journal Article
- Keywords:
Liver cirrhosis;
Varicose veins;
Clinical trial
- From:
Chinese Journal of Hepatology
2018;26(4):245-248
- CountryChina
- Language:Chinese
-
Abstract:
Gastroesophageal variceal bleeding is one of the major complications of cirrhosis and also the leading causes of death in patients with decompensated cirrhosis. Terlipressin is a triglycyl-lysine vasopressin, a synthetic vasopressin analogue that is mainly used for the treatment of acute variceal hemorrhage. This article aims to review the current status of treatment of gastroesophageal variceal bleeding with terlipressin from the perspective of evidence-based medicine.
